RNA-based drugs are emerging as a promising treatment for a number of diseases, including SARS-CoV-2. However, delivery vehicles that efficiently deliver RNA-based drugs are often limited to the liver, necessitating the optimization and discovery of new non-liver delivery vehicles. In this talk, I will discuss our pipeline for the identification of lipid nanoparticle (LNP)-based delivery vehicles, such as LNPs currently used by Pfizer and Moderna.